Emerging viral and bacterial infections of the central nervous system

Neurobehavioral HIV Medicine

Volumn 4, Issue 1, 2012, Pages 35-44

  Balin, Brian J ^a   Hammond, Christine J ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Bacteria; Central nervous system; Emergence; Viruses

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BISMUTH DERIVATIVE; CEFTRIAXONE; CLARITHROMYCIN; DOXYCYCLINE; METRONIDAZOLE; OMEPRAZOLE; OSELTAMIVIR; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ZANAMIVIR;

ACUTE DISEASE; ALZHEIMER DISEASE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BORRELIA BURGDORFERI; BORRELIA INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHIKUNGUNYA ALPHAVIRUS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CLIMATE CHANGE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; EHRLICHIA CHAFFEENSIS; ENTEROVIRUS 71; GASTRITIS; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HENIPAVIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN HERPESVIRUS 6; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS; JAPANESE ENCEPHALITIS VIRUS; JC VIRUS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEW SPECIES; NONHUMAN; ORIENTIA TSUTSUGAMUSHI; PARKINSON DISEASE; POLLUTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RICKETTSIOSIS; SPECIES IDENTIFICATION; TRAVEL; URBANIZATION; VIRUS ENCEPHALITIS; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS MENINGITIS; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 84863567862     PISSN: None     EISSN: 11791497     Source Type: Journal    
DOI: 10.2147/NBHIV.S24201     Document Type: Review

References (122)

1. Olival KJ, Daszak P. The ecology of emerging neurotropic viruses. J Neurovirol. 2005;11(5):441-446.
2. Tyler KL. Emerging viral infections of the central nervous system: part 1. Arch Neurol. 2009;66(8):939-948.
3. Tyler KL. Emerging viral infections of the central nervous system: part 2. Arch Neurol. 2009;66(9):1065-1074.
4. O'Sullivan JD, Allworth AM, Paterson DL, et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet. 1997; 349(9045):93-95.
5. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet. 1999;354(9186):1257-1259.
6. Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288(5470):1432-1435.
7. Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 2000; 342(17):1229-1235.
8. Lee KE, Umapathi T, Tan CB, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol. 1999; 46(3):428-432.
9. Tan CT, Goh KJ, Wong KT, et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol. 2002;51(6):703-708.
10. Wong KT, Shieh W, Kumar S, et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol. 2002;161(6):2153-2167.
11. Chadha MS, Comer JA, Lowe L, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis. 2006;12(2):235-240.
12. Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis. 2007;13(7):1031-1037.
13. Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55(8): 583-588.
14. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12(7):505-510.
15. Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood). 2011;236(8):899-908.
16. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9(1):78-85.
17. Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44(5):646-656.
18. Dauphin G, Zientara S, Zeller H, Murgue B. West Nile: worldwide current situation in animals and humans. Comp Immunol Microbiol Infect Dis. 2004;27(5):343-355.
19. Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis. 2004;23(3):147-156.
20. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1167-1173.
21. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001; 344(24):1807-1814.
22. Rappole JH, Compton BW, Leimgruber P, Robertson J, King DI, Renner SC. Modeling movement of West Nile virus in the Western hemisphere. Vector Borne Zoonotic Dis. 2006;6(2):128-139.
23. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174-1179.
24. Murray KO, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006; 134(6):1325-1332.
25. Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11(7):1021-1027.
26. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4): 511-515.
27. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009; 15(1):1-7.
28. Ghosh D, Basu A. Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis. 2009;3(9):e437.
29. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766-774, 774A-774E.
30. Solomon T. Control of Japanese encephalitis - within our grasp? N Engl J Med. 2006;355(9):869-871.
31. Pialoux G, Gaüzère B-, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007;7(5):319-327.
32. Robin S, Ramful D, Le Seach' F, Jaffar-Bandjee MC, Rigou G, Alessandri JL. Neurologic manifestations of pediatric chikungunya infection. J Child Neurol. 2008;23(9):1028-1035.
33. Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. Am J Neuroradiol. 2008;29(9):1636-1637.
34. Singh SS, Manimunda SP, Sugunan AP, Sahina P, Vijayachari P. Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect. 2008;136(9):1277-1280.
35. Das T, Jaffar-Bandjee MC, Hoarau JJ, et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog Neurobiol. 2010;91(2):121-129.
36. Couderc T, Chretien F, Schilte C, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008;4(2):e29.
37. Nero C. Chikungunya, the traveling virus. Clin Microbiol Newsl. 2008; 30(13):97-100.
38. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. New Engl J Med. 2007;356(8):769-771.
39. Schuffenecker I, Iteman I, Michault A, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 2006;3(7):1058-1070.
40. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007;3(12):e201.
41. Tsetsarkin KA, Weaver SC. Sequential adaptive mutations enhance efficient vector switching by chikungunya virus and its epidemic emergence. PLoS Pathog. 2011;7(12):e1002412.
42. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718-725.
43. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358(3):261-273.
44. Farooq O, Faden HS, Cohen ME, et al. Neurologic complications of 2009 influenza-A H1 N1 infection in children. J Child Neurol. 2011. Epub October 12, 2011.
45. Susser ES, Schaefer CA, Brown AS, Begg MD, Wyatt RJ. The design of the prenatal determinants of schizophrenia study. Schizophr Bull. 2000;26(2):257-273.
46. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61(8):774-780.
47. Fatemi SH, Emamian ES, Kist D, et al. Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry. 1999;4(2):145-154.
48. Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci. 2003;23(1):297-302.
49. Niu S, Renfro A, Quattrocchi CC, Sheldon M, D'Arcangelo G. Reelin promotes hippocampal dendrite development through the VLDLR/ ApoER2-Dab1 pathway. Neuron. 2004;41(1):71-84.
50. Davis LE. Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic. Curr Neurol Neurosci Rep. 2010;10(6):476-483.
51. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012. Epub February 27, 2012.
52. Engsig FN, Hansen A-E, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77-83.
53. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116-2128.
54. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-368.
55. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5): 743-747.
56. Berger JR. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep. 2007;7(6):461-469.
57. Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of US infants. J Clin Microbiol. 1993;31(2):416-418.
58. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988; 1(8594):1065-1067.
59. Yoshikawa T, Nakashima T, Suga S, et al. Human herpesvirus-6 DNA in cerebrospinal fluid of a child with exanthem subitum and meningoencephalitis. Pediatrics. 1992;89(5 Pt 1):888-890.
60. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432-438.
61. Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007;69(2):156-165.
62. Donati D, Akhyani N, Fogdell-Hahn A, et al. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology. 2003;61(10):1405-1411.
63. Fotheringham J, Donati D, Akhyani N, et al. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med. 2007; 4(5):e180.
64. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003;187(9):1365-1376.
65. Chan PKS, Ng HK, Hui M, Ip M, Cheung JLK, Cheng AF. Presence of human herpesviruses 6, 7, and 8 DNA sequences in normal brain tissue. J Med Virol. 1999;59(4):491-495.
66. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46(11):1724-1743.
67. Olli-Lahdesmaki T, Haataja L, Parkkola R, Waris M, Bleyzac N, Ruuskanen O. High-dose ganciclovir in HHV-6 encephalitis of an immunocompetent child. Pediatr Neurol. 2010;43(1):53-56.
68. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006;71(2-3):141-148.
69. Jamieson GA, Maitland NJ, Craske J, Wilcock GK, Itzhaki RF. Detection of herpes simplex virus type 1 DNA sequences in normal and Alzheimer's disease brain using polymerase chain reaction. Biochem Soc Trans. 1991;19(2):122S.
70. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009; 217(1):131-138.
71. Wozniak MA, Shipley SJ, Combrinck M, Wilcock GK, Itzhaki RF. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. J Med Virol. 2005;75(2):300-306.
72. Letenneur L, Pérès K, Fleury H, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One. 2008;3(11):e3637.
73. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease [see comments]. Lancet. 1997;349(9047):241-244.
74. Cheng SB, Ferland P, Webster P, Bearer EL. Herpes simplex virus dances with amyloid precursor protein while exiting the cell. PLoS One. 2011;6(3):e17966.
75. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009;16(2):341-350.
76. Benetti L, Roizman B. Herpes simplex virus protein kinase Us3 activates and functionally overlaps protein kinase A to block apoptosis. Proc Natl Acad Sci U S A. 2004;101(25):9411-9416.
77. Santana S, Recuero M, Bullido MJ, Valdivieso F, Aldudo J. Herpes simplex virus type I induces the accumulation of intracellular betaamyloid in autophagic compartments and the inhibition of the nonamyloidogenic pathway in human neuroblastoma cells. Neurobiol Aging. 2012;33(2):430.e19-e33. Epub January 26, 2011.
78. Wozniak MA, Frost AL, Preston CM, Itzhaki RF. Antivirals reduce the formation of key alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One. 2011; 6(10):e25152.
79. McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol. 2011;11(5):318-329.
80. Drevets DA, Leenen PJ, Greenfield RA. Invasion of the central nervous system by intracellular bacteria. Clin Microbiol Rev. 2004;17(2): 323-347.
81. Henry CS, Overbeek R, Xia F, et al. Connecting genotype to phenotype in the era of high-throughput sequencing. Biochim Biophys Acta. 2011; 1810(10):967-977.
82. Watt G, Parola P. Scrub typhus and tropical rickettsioses. Curr Opin Infect Dis. 2003;16(5):429-436.
83. Kelly DJ, Fuerst PA, Ching WM, Richards AL. Scrub typhus: The geographic distribution of phenotypic and genotypic variants of Orientia tsutsugamushi. Clin Infect Dis. 2009;48(Suppl 3):S203-S230.
84. Kim DE, Lee SH, Park KI, Chang KH, Roh JK. Scrub typhus encephalomyelitis with prominent focal neurologic signs. Arch Neurol. 2000; 57(12):1770-1772.
85. Mahajan SK, Rolain J, Kanga A, Raoult D. Scrub typhus involving central nervous system, India, 2004-2006. Emerg Infect Dis. 2010;16(10): 1641-1643.
86. Rajapakse S, Rodrigo C, Fernando SD. Drug treatment of scrub typhus. Trop Doct. 2011;41(1):1-4.
87. Olano JP, Hogrefe W, Seaton B, Walker DH. Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. Clin Diagn Lab Immunol. 2003;10(5):891-896.
88. Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL. Human monocytic ehrlichiosis and human granulocytic anaplasmosis in the United States, 2001-2002. Ann NY Acad Sci. 2006;1078: 118-119.
89. Olano JP, Masters E, Hogrefe W, Walker DH. Human monocytotropic ehrlichiosis, Missouri. Emerg Infect Dis. 2003;9(12):1579-1586.
90. Marshall GS, Jacobs RF, Schutze GE, et al. Ehrlichia chaffeensis seroprevalence among children in the southeast and south-central regions of the United States. Arch Pediatr Adolesc Med. 2002;156(2):166-170.
91. Anderson BE, Sims KG, Olson JG, et al. Amblyomma americanum: a potential vector of human ehrlichiosis. Am J Trop Med Hyg. 1993; 49(2):239-244.
92. Ratnasamy N, Everett ED, Roland WE, McDonald G, Caldwell CW. Central nervous system manifestations of human ehrlichiosis. Clin Infect Dis. 1996;23(2):314-319.
93. Rikihisa Y. Ehrlichia subversion of host innate responses. Curr Opin Microbiol. 2006;9(1):95-101.
94. Dierberg KL, Dumler JS. Lymph node hemophagocytosis in rickettsial diseases: a pathogenetic role for CD8 T lymphocytes in human monocytic ehrlichiosis (HME)? BMC Infect Dis. 2006;6:121.
95. Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin Lab Med. 2010;30(1):261-292.
96. Thomas RJ, Dumler JS, Carlyon JA. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther. 2009;7(6): 709-722.
97. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161: 618-625.
98. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis. 1998;177(5):1322-1325.
99. Balin BJ, Gerard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl). 1998;187(1):23-42.
100. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology. 1998;50(298145402):571-572.
101. Balin BJ, Little CS, Hammond CJ, et al. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis. 2008;13(4):371-380.
102. Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. Chlamydophila pneumoniae infection and its role in neurological disorders. Interdiscip Perspect Infect Dis. 2010;2010:273573. Epub February 21, 2010.
103. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004;25(4):419-429.
104. Little CS, Bowe A, Lin R, et al. Age alterations in extent and severity of experimental intranasal infection with Chlamydophila pneumoniae in BALB/c mice. Infect Immun. 2005;73(3):1723-1734.
105. Boelen E, Steinbusch HW, Bruggeman CA, Stassen FR. The inflammatory aspects of Chlamydia pneumoniae-induced brain infection. Drugs Today (Barc). 2009;45(Suppl B):159-164.
106. Appelt DM, Roupas MR, Way DS, et al. Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae. BMC Neurosci. 2008;9:13.
107. Thiem U, Heppner HJ, Pientka L. Elderly patients with communityacquired pneumonia: optimal treatment strategies. Drugs Aging. 2011; 28(7):519-537.
108. Loeb MB, Molloy DW, Smieja M, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52(3):381-387.
109. Rupprecht TA, Koedel U, Fingerle V, Pfister HW. The pathogenesis of lyme neuroborreliosis: from infection to inflammation. Mol Med. 2008;14(3-4):205-212.
110. MacDonald AB, Miranda JM. Concurrent neocortical borreliosis and Alzheimer's disease. Hum Pathol. 1987;18(7):759-761.
111. Miklossy J. Alzheimer's disease - a spirochetosis? Neuroreport. 1993; 4(7):841-848.
112. Miklossy J, Kis A, Radenovic A, et al. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 2006;27(2):228-236.
113. O'Connell S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis. 2010;23(3):231-235.
114. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863-1873.
115. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses. 2000;55(2):93-98.
116. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand. 1999;99(1):26-35.
117. Weller C, Charlett A, Oxlade NL, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter. 2005;10(4):288-297.
118. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol. 2012. Epub January 17, 2012.
119. Gerhard M, Rad R, Prinz C, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2002;7(Suppl 1):17-23.
120. Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 2003;71(4):1755-1762.
121. Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA. Helicobacter pylori and extragastric diseases - other Helicobacters. Helicobacter. 2004;9(Suppl 1):57-66.
122. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011;17(35):3971-3975.